Management team
 | Dianne Blanco – Chief Executive OfficerMrs Blanco spent 14 years at Baxter Healthcare growing medical device/pharmaceutical divisions in the US, Europe and globally. She started at Baxter leading a new initiative to build a division to develop market products for healthcare outside the hospital a non-traditional market for Baxter. In three years, she built the division to over $200 million in sales. In her latest position she spent over five years as President of the European division with P&L responsibility for more than 500 employees and over three-quarters of a billion dollars in sales. The organization grew almost 20 percent annually in the last three years. She was responsible for bringing many new products to market during her tenure, including a critical care therapy that revitalized a large division and moved it from a distant number three in the market to market leader. |
 | David W Anderson – ChairmanMr Anderson has been a successful entrepreneur in the orthopaedic medical device field for over 20 years. He has led four orthopaedic organizations; Osteotech (Executive VP), Bionx Implants (CEO), Replication Medical (Founder and Director), and Gentis (CEO). Mr. Anderson was a founder of Osteotech and was the founder and CEO of Bionx Implants which he grew through over 60 product approvals to over $20 million in sales in less than three years. He was also part of the team that created Integra LifeSciences and was an active member of the Board of Directors of Replication Medical. He has raised over $150 million in venture capital, taken a company through the IPO route onto NASDAQ, and has been a part of multiple M&A transactions. |
 | Shaun Claydon ACA – Chief Financial OfficerMr. Claydon has over 16 years experience as a corporate financier, latterly within the UK investment banking industry. During his career he has advised a wide range of companies on fundraising, M&A and private equity transactions both in the UK and International public and private markets. Mr. Claydon has advised numerous UK Life Science companies on IPOs, secondary offerings and other corporate transactions. A qualified chartered accountant, he has held senior positions within corporate finance at PwC, Evolution Securites and HSBC Investment Banking. |
 | Simon Coles – Vice President, Global Sales and MarketingMr Coles’ career spans two decades of consistent achievement in Healthcare Sales and Marketing, with Smith & Nephew and Baxter. He has launched medical devices that have pioneered new treatments in the fields of biosurgery, wound care, orthobiologics and tissue regeneration. Operating at a global level he has worked extensively throughout Europe, Asia and the United States. Mr. Coles was Head of US Marketing from 2002-2005, helping to build the Baxter Biosurgery business to $125million revenue. His other role at Baxter was as Head of Global Marketing and Strategy with the Baxter Biosurgery unit. During this period at Baxter he was a member of the senior management team that created a new, global, direct sales franchise in surgery, with revenues of $260million, growing at 22% per annum. |
 | Michael Shin, Ph.D. – Director R&DDr. Shin has extensive expertise in biomaterials, regenerative medicine and materials engineering. He has a long track record of interdisciplinary research with clinicians and basic scientists. He has published over 50 publications in the scientific and medical literature, and given more than 30 invited lectures across the world. |
 | Matthew Womack, Phd – Head of Global Medical AffairsDr Womack has over ten years of preclinical and clinical research experience, and has published numerous peer-reviewed papers in international journals. After receiving his PhD in neuropharmacology from the University of Bradford, he went on to carry out postdoctoral research for the British Heart Foundation at the University of Liverpool. Subsequently, he moved into orthopaedic clinical research with Depuy International (a Johnson & Johnson company), before going on to hold further clinical research and Medical Affairs positions within the pharmaceutical industry. |